Aditxt (NASDAQ:ADTX) stock is rising higher on Wednesday after the company notified investors of an update on a clinical trial conducted by its subsidiary Pearsanta.According to a press release from Aditxt, Pearsanta has submitted a Clinical Trial Translational Endpoints Research Award proposal to the Congressionally Directed Medical Research Programs (CDMRP) of the Department of Defense.Aditxt notes that this proposal seeks to validate a novel assay based on Pearsanta’s Mitomic Technology. The goal would b ...